drugset / Trial / NCT03817970
Cisplatin Disposition and Kidney Injury
Phase 3
Active not recruiting
72 enrolled
University of Colorado, Denver
Memorial Sloan Kettering Cancer Center · collabNational Institute of General Medical Sciences (NIGMS) · collabRutgers University · collab
RandomizedParallel-groupOpen-labelBasic science
Summary
This study is being done to determine 1) whether drugs to treat cisplatin-related nausea can influence harm to the kidneys, 2) whether cisplatin levels in the body can influence the risk of harm to the kidneys, and 3) whether a person's genetic make-up can increase or decrease the likelihood of kidney injury due to cisplatin therapy.
Timeline
- Start
- 2019-11-15
- Primary completion
- 2027-09-30
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Granisetron | Other / unclassified | 2 mg | Oral |
| Subject | Ondansetron | Other / unclassified | 8 mg | Oral |
| Subject | Palonosetron | Other / unclassified | 0.25 mg | Intravenous |